The FIND-CKD trial randomised adult patients with non-dialysis-dependent CKD, anaemia and iron deficiency to receive high-ferritin IV iron (n = 155), low-ferritin IV iron (n = 154) or oral iron (n = 317). Patients treated with higher ferritin quickly reached and maintained the Hb target (increase ≥1 g/dl) and were less likely to require ESA treatment compared with the other treatment arms. No significant differences in QoL outcomes were observed between the treatment arms. Here, GSTM1 is linked to chronic kidney disease.